Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Nocturnal asthma-like symptoms tied to obstructive sleep apnoea risk

01 Dec 2019

Symptoms of obstructive sleep apnoea (OSA) are similar to some nocturnal asthma-like symptoms (NAS), suggests a recent study.

“OSA and asthma are associated, and nocturnal breathing difficulty that is usually identified as asthma-like symptoms can be present in both conditions,” the authors said.

This study examined how NAS and bronchial hyper-reactivity (BHR) contributed to the link between OSA risk and current asthma. Data were obtained from 794 middle-aged participants (mean age, 50 years; 49.8 percent male) in a population-based cohort with available information on OSA risk (defined by a STOP-Bang questionnaire score of at least 3), current asthma and NAS and underwent methacholine bronchial challenge testing.

The authors used regression models to examine the association between OSA risk and current asthma-NAS subgroups and to probe any effect modification by BHR.

OSA risk correlated with NAS with (odds ratio [OR], 2.6, 95 percent confidence interval [CI], 1.3–5.0) or without current asthma (OR, 4.2, 95 percent CI, 1.1–16.1), but not with current asthma in the absence of NAS. BHR correlated with current asthma with (OR, 2.9, 95 percent CI, 1.4–5.9) or without NAS (OR, 3.4, 95 percent CI, 2.0–7.0), but not with NAS in the absence of current asthma. Of note, BHR neither modified nor mediated the associations between OSA risk and current asthma.

“Patients with nocturnal asthma symptoms should be considered for possible OSA,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.